Randomized Trial of Enteral ARA and DHA Supplementation to Prevent Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants at Aristotle University of Thessaloniki

What this Trial Is About

This research aims to evaluate the effect of supplementing extremely and very preterm infants, born between 24 and 29 weeks of gestational age, with omega-3 DHA and omega-6 ARA fatty acids on the development of bronchopulmonary dysplasia BPD. The study is focused on preventing BPD, a lung condition in premature infants, by comparing infants who receive this supplementation to those who receive standard care. Participants in the intervention group will receive enteral supplementation containing ARA and DHA in a 21 ratio starting within the first three days of life and continuing until 36 weeks postmenstrual age. The control group will receive routine clinical care and nutritional support without the additional supplementation. Both groups will be monitored until 36 weeks postmenstrual age. During the study, infants will be assessed for the presence or absence of BPD based on their need for respiratory support or supplemental oxygen at 36 weeks postmenstrual age. Additional outcomes include the classification of BPD, occurrence of related complications, respiratory support needs, oxygen and ventilation measures, steroid use, and growth changes. The study lasts from birth until 36 to 40 weeks postmenstrual age, with regular clinical evaluations conducted throughout this period.

Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants